Current reports
6-K
Current report (foreign)
21 Mar 24
6-K
Current report (foreign)
16 Nov 23
6-K
Current report (foreign)
22 Aug 23
6-K
Current report (foreign)
15 Aug 23
6-K
Lava Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
15 Jun 23
6-K
Current report (foreign)
8 Jun 23
6-K
Gamma delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation April 2023
24 Apr 23
6-K
Lava Therapeutics Provides Business Update and Reports Fourth Quarter and Year-end 2022 Financial Results
12 Apr 23
6-K
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
13 Mar 23
6-K
Current report (foreign)
16 Feb 23
Registration and prospectus
F-3
Shelf registration (foreign)
12 Apr 22
S-8
Registration of securities for employees
28 May 21
424B4
Prospectus supplement with pricing info
26 Mar 21
F-1/A
Registration statement (foreign) (amended)
24 Mar 21
8-A12B
Registration of securities on exchange
18 Mar 21
F-1/A
Registration statement (foreign) (amended)
18 Mar 21
F-1
Registration statement (foreign)
2 Mar 21
DRS
Draft registration statement
25 Jan 21
Proxies
No filings
Other
UPLOAD
Letter from SEC
4 Jan 23
CORRESP
Correspondence with SEC
12 Dec 22
UPLOAD
Letter from SEC
29 Nov 22
EFFECT
Notice of effectiveness
22 Apr 22
CORRESP
Correspondence with SEC
20 Apr 22
UPLOAD
Letter from SEC
19 Apr 22
EFFECT
Notice of effectiveness
25 Mar 21
CERT
Certification of approval for exchange listing
24 Mar 21
SEC STAFF
SEC staff action: Order
24 Mar 21
CORRESP
Correspondence with SEC
23 Mar 21
Ownership
SC 13D/A
Novo Holdings A/S
7 Mar 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13D/A
Novo Holdings A/S
9 Nov 23
SC 13D/A
Novo Holdings A/S
6 Jun 23
144
Notice of proposed sale of securities
5 Jun 23
SC 13D/A
Novo Holdings A/S
24 Feb 23
SC 13D/A
Novo Holdings A/S
3 Oct 22
SC 13D/A
Novo Holdings A/S
30 Sep 22
SC 13G/A
Redmile Group, LLC
14 Feb 22
SC 13D
Versant Venture Capital VI, L.P.
8 Apr 21